Navigation Links
Immtech Investor Conference Call Scheduled for February 11, 2008
Date:2/6/2008

release contains forward-looking statements regarding Immtech's business, including the future prospects for PCP. Except for historical information, the matters discussed in this press release are forward-looking statements and are subject to risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to the following: (i) Immtech's ability to develop commercially viable products; (ii) Immtech's ability to achieve profitability; (iii) Immtech's ability to retain key personnel; (iv) the ability of Immtech's scientists and collaborators to discover new compounds; (v) the availability of additional research grants; (vi) Immtech's ability to obtain regulatory approval of its drug candidates, including PCP; (vii) the success of Immtech's clinical trials; (viii) Immtech's dependence upon and contractual relationship with partners; (ix) Immtech's ability to manufacture or to contract with a third party to manufacture its drug candidates at reasonable costs; (x) Immtech's ability to protect its intellectual property; (xi) competition and alternative technologies; (xii) Immtech's ability to obtain reimbursement from third party payers for any product it commercializes; and (xiii) Immtech's potential exposure to significant product liability.

Additional risks are discussed in Immtech's current filings with the Securities and Exchange Commission. Although Immtech believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. The forward-looking statements are made as of the date of this press release, and Immtech undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.


'/>"/>
SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine
2. Immtech to Present at The Bank of Montreal Healthcare Conference
3. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
5. Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
6. PharmAthene to Present at the BIO CEO & Investor Conference 2008
7. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
8. Iomai CEO to Speak at BIO CEO & Investor Forum on Feb. 12
9. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
10. Rigel to Present at BIO CEO & Investor Conference
11. Cell Therapeutics, Inc. (CTI) to Present at 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 Not long ago, it ... should be performed late in the development cycle – ... current regulatory trends suggest that, like many things GxP, ... In recent years, multiple drug sponsors have been required ... specific questions during phase I/II. It’s not only clinical ...
(Date:8/20/2014)... GraphDB™ 6.0 from ... to the enterprise replication cluster, faster loading speeds, ... and Elasticsearch. This release happens to coincide with ... – GraphDB™ was formerly known as OWLIM. ... mature enterprise resilient RDF triplestore will also benefit ...
(Date:8/19/2014)... Aug. 19, 2014 A Geisinger researcher on ... for a Centers for Disease Control and Prevention (CDC) ... public health concern. Joseph Boscarino , ... of a team of researchers nominated for the Centers ... Science Award for Data Methods and Study Design. ...
(Date:8/19/2014)... KS (PRWEB) August 19, 2014 ... offer fast and cost-effective metabolite production from bioactive ... proprietary chemistry platform, the technology enables convenient and ... According to XenoTech’s Vice President of Commercial ... synthesis for assessing clinical risk can be measured ...
Breaking Biology Technology:Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3
... 2011 Verenium Corporation (Nasdaq: VRNM ), ... and commercialization of high-performance enzymes, today announced that it ... at the second annual Bright Lights Conference in New ... is the only conference with an exclusive focus on ...
... Responding quickly to the FDA,s proclaimed new limits ... Laboratories, Inc., http://www.pisgahlabs.com , files a patent ... products. Filed with the US Patent & Trademark ... is the eighteenth filing for Pisgah and represents ...
... of API analytical standards Epichem, announced today it has ... Life Sciences supplier company, AR Brown, for sales to ... in Tokyo, AR Brown is one of Japan,s largest ... have earned the reputation as a strong and reliable ...
Cached Biology Technology:Verenium Receives CLARUS Award at MDB Capital's Bright Lights Conference 2011 2Verenium Receives CLARUS Award at MDB Capital's Bright Lights Conference 2011 3Verenium Receives CLARUS Award at MDB Capital's Bright Lights Conference 2011 4Latest Addition to Patent Portfolio Hammers Prescription Drug Abuse and Creates New Market 2Latest Addition to Patent Portfolio Hammers Prescription Drug Abuse and Creates New Market 3Epichem and AR Brown Sign Exclusive Distribution Agreement for Japan, Taiwan, China and South Korea 2Epichem and AR Brown Sign Exclusive Distribution Agreement for Japan, Taiwan, China and South Korea 3
(Date:8/20/2014)... Huntsman Cancer Institute (HCI) at the University of Utah ... that encodes BCR-ABL, the unregulated enzyme driving the blood ... Cancer Society, nearly 6,000 new cases of CML will ... called tyrosine kinase inhibitors (TKIs), target BCR-ABL and are ... CML but control it in a way that allows ...
(Date:8/20/2014)... Tbingen, Arizona State University, the Wellcome Trust Sanger Institute ... TPH) isolated Mycobacterium pinnipedii from skeletons found ... The pathogen is a relative of the TB bacterium ... humans today. These researchers assume that seals carried the ... to sea lions was unexpected" comments Sebastien Gagneux, from ...
(Date:8/20/2014)... -- Bay Area Lyme Foundation, which aims to make ... applauds new research published in an upcoming issue of ... Diseases . The findings show that ticks that ... the year, making the threat of Lyme disease year-round. ... of Public Health (CDPH) Vector-borne Disease Section and University ...
Breaking Biology News(10 mins):Blueprint for next generation of chronic myeloid leukemia treatment 2Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3
... TORONTO, Ont., June 21, 2011Researchers at St. Michael,s Hospital ... for patients with kidney failure. Cells that help protect ... home during the night than those who undergo standard daytime ... nephrologist. This is important for patients with kidney ...
... Calif., June 21, 2011 DigitalPersona, Inc. , ... today announced Sailormen, Inc. , the largest Popeye,s ... out U.are.U® Fingerprint Readers to 148 locations ... Sailormen, Inc. has found that the deployment of fingerprint ...
... Rochelle, a professor at The University of Texas at ... the Donald L. Katz Award from the Gas Processors ... during the organization,s annual convention in San Antonio and ... engineering education. , "Gary has a long history ...
Cached Biology News:New evidence of the benefits of home dialysis for kidney patients 2Popeye's Restaurant Franchisee Uses DigitalPersona Fingerprint Biometrics to Reduce Employee Fraud 2Popeye's Restaurant Franchisee Uses DigitalPersona Fingerprint Biometrics to Reduce Employee Fraud 3University of Texas at Austin professor receives Donald L. Katz Award 2
...
... PowerEase 500 Power Supply is ... It offers extensive programming capabilities ... custom methods for you to ... The simple intuitive PowerEase interface ...
... Transformation Buffer Set are convenient methods for ... for simple and highly efficient DNA transformation. ... for heat shocking and related procedures. Instead, ... adding DNA to Z-Competent cells and incubating ...
Buffer used for mitocapture assays....
Biology Products: